Intra articular steroid injection complications

Home  |  About Us  |  Our Providers  |  Careers  |  Services  |  Conditions & Treatments  |  Patient Information  |  Referring Offices  |  Locations  |  Offices
Schedule An Appointment  |  New Patient Packet  |  Refer A Patient  |  New Patient Referral Form  |  Procedure Specific Referral Form
Notice of Privacy Practices  |  Website Privacy Policy  |  Legal Notice/Disclaimer

In common with other corticosteroids, triamcinolone is metabolised largely hepatically but also by the kidney and is excreted in urine. The main metabolic route is 6-beta-hydroxylation; no significant hydrolytic cleavage of the acetonide occurs. In view of the hepatic metabolism and renal excretion of triamcinolone acetonide, functional impairments of the liver or kidney may affect the pharmacokinetics of the drug. This may become clinically significant if large or frequent doses of intradermal or intra-articular triamcinolone acetonide are given.

The steroid medication begins to take effect in one to two days at which point you should start to see some benefit. The steroid effect continues to increase with the peak effect occurs at about two weeks. Thereafter, the effect will stabilize and should last several weeks to months. Typically, the pain relief experienced from this procedure lasts 3-6 months, but there is significant variability from patient to patient and from one procedure to another. If and when the pain starts to return, this procedure can be repeated to try and attain some pain relief once again. Keep in mind that this injection may work very well for pain certain areas but may not help with others. This is normal. Areas of pain that do not respond may need other treatments, which you can discuss with your doctor.

An assessment of viscosupplementation for knee OA by the Canadian Agency for Drugs and Technologies in Health (CADTH) (Dagenais, 2006) found that evidence suggests modest short-term reductions in pain and improvements in function, and no superiority among viscosupplement products.  Adverse events are rare, benign, temporary, and likely associated with the intra-articular injection.  The assessment reported that clinical practice guidelines and evidence suggest that this approach is most suitable for patients with mild to moderate knee OA, and in those for whom other approaches are contraindicated, or have failed.

Intra articular steroid injection complications

intra articular steroid injection complications

An assessment of viscosupplementation for knee OA by the Canadian Agency for Drugs and Technologies in Health (CADTH) (Dagenais, 2006) found that evidence suggests modest short-term reductions in pain and improvements in function, and no superiority among viscosupplement products.  Adverse events are rare, benign, temporary, and likely associated with the intra-articular injection.  The assessment reported that clinical practice guidelines and evidence suggest that this approach is most suitable for patients with mild to moderate knee OA, and in those for whom other approaches are contraindicated, or have failed.

Media:

intra articular steroid injection complicationsintra articular steroid injection complicationsintra articular steroid injection complicationsintra articular steroid injection complicationsintra articular steroid injection complications